BITRF (Biotron) Institutional Ownership: 0.04% (As of Jul. 12, 2026)


What is Biotron Institutional Ownership?

Biotron BITRF Institutional Ownership is 0.04% as of Jul. 12, 2026. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biotron's institutional ownership is 0.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biotron's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biotron's Float Percentage Of Total Shares Outstanding is 0.00%.

Biotron Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Biotron's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotron Institutional Ownership Chart

Biotron Historical Data

The historical data trend for Biotron can be seen below:

2023-12-31
Institutional Ownership 0.04

Biotron Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.04% mean?
Biotron (BITRF) has a Institutional Ownership of 0.04% as of Jul. 12, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Biotron and its competitors.
Is Biotron's Institutional Ownership too high?
Biotron's current Institutional Ownership is 0.04%.
How does Biotron's Institutional Ownership compare to VRTX and REGN?
Biotron's Institutional Ownership of 0.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Biotron and its competitors. Biotron's current Institutional Ownership is 0.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotron stock overvalued right now?
Biotron (BITRF) has a current Institutional Ownership of 0.04%. The current Institutional Ownership is 0.04%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Biotron (BITRF), the current Institutional Ownership is 0.04% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotron Business Description

Other Exchanges BIT:Australia
Address 66 Hunter Street, Level 2, Sydney, NSW, AUS, 2000
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.